Salmi H A
Central Military Hospital, Helsinki, Finland.
J Chemother. 1993 Dec;5(6):532-6.
Brodimoprim was studied in the treatment of acute respiratory tract infections in hospitalized, basically healthy, military conscripts. Its efficacy and tolerance were compared to those of doxycycline in a clinical randomized double-blind trial. 60 pts. were divided into two equally large groups. One group received brodimoprim, 400 mg as a loading dose followed by 200 mg daily, for 10 days. The other group received doxycycline, 200 mg as a loading dose followed by 100 mg daily, for 10 days. In the brodimoprim group, 23 patients (77%) were cured, 5 patients (16%) improved and 2 patients (6%) were considered failures. In the doxycycline group, 26 patients (87%) were cured, 3 patients (10%) improved and 1 patient (3%) did not respond. The only side effect in the whole study was moderate diarrhea in 1 patient in the brodimoprim group. Clinically and according to the normalization of laboratory values, the two drugs tested were equally effective.
对住院的、基本健康的应征入伍军人，研究了溴莫普明治疗急性呼吸道感染的效果。在一项临床随机双盲试验中，将其疗效和耐受性与强力霉素进行了比较。60名患者被分为两个同等规模的组。一组接受溴莫普明治疗，首剂400mg，随后每日200mg，共10天。另一组接受强力霉素治疗，首剂200mg，随后每日100mg，共10天。在溴莫普明组，23例患者（77%）治愈，5例患者（16%）病情改善，2例患者（6%）被视为治疗失败。在强力霉素组，26例患者（87%）治愈，3例患者（10%）病情改善，1例患者（3%）无反应。整个研究中唯一的副作用是溴莫普明组有1例患者出现中度腹泻。从临床和实验室指标正常化情况来看，所测试的两种药物疗效相当。
